Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Myasthenia Gravis × inebilizumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 2 Recurrence 1 Neoplasms 1 Myasthenia Gravis 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hematologic Neoplasms 1

Interventions

rozanolixizumab 4 eculizumab 4 zilucoplan 3 efgartigimod alfa 3 Rituximab 2 Prednisone 2 Amifampridine 2 thymoglobulin 1 satralizumab 1 rhoA GTP-Binding Protein 1 ravulizumab 1 inebilizumab 1 gamma-Globulins 1 Thymectomy 1 Sugars 1 Steroids 1 Sodium Chloride 1 Robotic Surgical Procedures 1 Prednisolone 1 Methylprednisolone 1 Methotrexate 1 Mesna 1 Hizentra 1 Hematopoietic Stem Cell Transplantation 1 Granulocyte Colony-Stimulating Factor 1 Fluid Therapy 1 Cyclophosphamide 1 Acupuncture Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04524273 2026-03-10

MINT

Amgen

Phase 3 Active not recruiting

238 enrolled 36 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡